Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
19.51
+0.61 (3.23%)
Jan 8, 2025, 4:00 PM EST - Market closed
Nurix Therapeutics Employees
Nurix Therapeutics had 284 employees as of November 30, 2023. The number of employees decreased by 13 or -4.38% compared to the previous year.
Employees
284
Change (1Y)
-13
Growth (1Y)
-4.38%
Revenue / Employee
$198,676
Profits / Employee
-$623,155
Market Cap
1.38B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Nov 30, 2023 | 284 | -13 | -4.38% |
Nov 30, 2022 | 297 | 55 | 22.73% |
Nov 30, 2021 | 242 | 107 | 79.26% |
Nov 30, 2020 | 135 | 42 | 45.16% |
Nov 30, 2019 | 93 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
NRIX News
- 2 days ago - Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 20 days ago - Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia - GlobeNewsWire
- 4 weeks ago - Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting - GlobeNewsWire
- 5 weeks ago - Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 6 weeks ago - Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia - GlobeNewsWire
- 7 weeks ago - Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024 - GlobeNewsWire
- 2 months ago - Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire